Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tavapadon - Cerevel Therapeutics

Next Previous
X
Search
Drug Profile

Tavapadon - Cerevel Therapeutics

Alternative Names: CVL 751; PF 6649751; PF-06649751

Latest Information Update: 15 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Cerevel Therapeutics; Pfizer
  • Class Antiparkinsonians; Small molecules
  • Mechanism of Action Dopamine D1 receptor agonists; Dopamine D5 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Parkinson's disease

Most Recent Events

  • 01 Oct 2024 Cerevel Therapeutics completes a phase III clinical trials in Parkinson's disease (Early-stage disease) in Taiwan, Thailand, South Korea, Spain, Serbia, Poland, South Korea, Italy, Hungary, Germany, France, Australia and USA (PO) (NCT04223193)
  • 27 Sep 2024 Efficacy and adverse events data from a phase III trial in Parkinson's disease released by AbbVie
  • 01 Aug 2024 Cerevel Therapeutics has been acquired by AbbVie

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top